醒脑开窍针刺法联合重复经颅磁刺激治疗肝郁气滞型脑卒中后抑郁临床研究OA
Clinical Study on Xingnao Kaiqiao Acupuncture Combined with Repetitive Transcranial Magnetic Stimulation for Post-Stroke Depression of Liver Qi Stagnation Type
目的:观察在脑卒中恢复期常规对症治疗基础上采用醒脑开窍针刺法联合重复经颅磁刺激(rTMS)治疗肝郁气滞型脑卒中后抑郁(PSD)的临床效果.方法:纳入2022年1月—2024年12月金华市中心医院康复科收治的88例肝郁气滞型PSD患者,按随机数字表法分为研究组、对照组各44例.2组均予脑卒中恢复期常规对症治疗,对照组予rTMS治疗,研究组予醒脑开窍针刺法联合rTMS治疗,2组均治疗3周.治疗前后评估中医证候评分、神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)评分]、抑郁程度[24项汉密尔顿抑郁量表(HAMD-24)评分]、睡眠质量[匹兹堡睡眠质量指数量表(PSQI)评分],检测血清单胺类神经递质[5-羟色胺(5-HT)、多巴胺(DA)、去甲肾上腺素(NE)]、脑源性神经营养因子(BDNF)、炎症因子[白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)]水平.比较2组的临床疗效及不良反应发生率.结果:治疗3周后,研究组总有效率高于对照组(P<0.05).2组中医证候积分、NIHSS评分、HAMD-24评分及PSQI评分均较治疗前降低(P<0.05),研究组4项评分均低于对照组(P<0.05).2组血清5-HT、DA、NE、BDNF水平均较治疗前升高(P<0.05),血清IL-1β、IL-6水平均较治疗前下降(P<0.05).研究组血清5-HT、DA、NE、BDNF水平均高于对照组(P<0.05),血清IL-1β、IL-6水平均低于对照组(P<0.05).2组不良反应发生率比较,差异无统计学意义(P>0.05).结论:在脑卒中恢复期常规对症治疗基础上采用醒脑开窍针刺法联合rTMS治疗肝郁气滞型PSD患者疗效显著,在缓解临床症状、减轻神经功能缺损程度及抑郁程度、提高睡眠质量方面均有积极效果,安全性较好.其作用机制可能与调节单胺类神经递质、BDNF水平及减轻炎症反应有关.
Objective:To observe the clinical efficacy of Xingnao Kaiqiao acupuncture combined with repetitive transcranial magnetic stimulation(rTMS)on the basis of routine symptomatic treatment during the recovery phase of stroke for post-stroke depression(PSD)of liver qi stagnation type.Methods:A total of 88 PSD patients of liver qi stagnation type admitted to Department of Rehabilitation,Jinhua Municipal Central Hospital from January 2022 to December 2024 were enrolled and randomly divided into the study group and the control group using the random number table method,with 44 cases in each group.Both groups received routine symptomatic treatment during the stroke recovery phase.The control group received additional rTMS treatment,while the study group received Xingnao Kaiqiao acupuncture combined with rTMS.Both groups were treated for three weeks.Before and after treatment,traditional Chinese medicine syndrome scores,neurological deficit severity[National Institutes of Health Stroke Scale(NIHSS)score],depression severity[24-item Hamilton Depression Rating Scale(HAMD-24)score],and sleep quality[Pittsburgh Sleep Quality Index(PSQI)score]were assessed.Serum levels of monoamine neurotransmitters[5-hydroxytryptamine(5-HT),dopamine(DA),norepinephrine(NE)],brain-derived neurotrophic factor(BDNF),and inflammatory factors[interleukin-1β(IL-1β),interleukin-6(IL-6)]were measured.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results:After three weeks of treatment,the total effective rate in the study group was superior to that in the control group(P<0.05).Scores of traditional Chinese medicine syndrome,NIHSS,HAMD-24,and PSQI decreased in both groups compared with those before treatment(P<0.05),and all four scores were lower in the study group than in the control group(P<0.05).Serum levels of 5-HT,DA,NE,and BDNF increased in both groups compared with those before treatment(P<0.05),while serum levels of IL-1β and IL-6 decreased(P<0.05).The study group showed higher serum levels of 5-HT,DA,NE,and BDNF(P<0.05)and lower serum levels of IL-1β and IL-6(P<0.05)compared with those in the control group.No statistically significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:On the basis of routine symptomatic treatment during the stroke recovery phase,Xingnao Kaiqiao acupuncture combined with rTMS demonstrates significant efficacy in the treatment of PSD patients of liver qi stagnation type.It positively alleviates clinical symptoms,reduces neurological deficit and depression severity,and improves sleep quality,with good safety.The mechanism of action may be related to regulating monoamine neurotransmitter and BDNF levels,as well as reducing inflammatory responses.
项鹏慧;朱玲钰;滕启飞
金华市中心医院康复科,浙江 金华 321000金华市中心医院康复科,浙江 金华 321000金华市中心医院康复科,浙江 金华 321000
医药卫生
脑卒中后抑郁肝郁气滞证醒脑开窍针刺法重复经颅磁刺激抑郁程度睡眠质量神经递质炎症因子
Post-stroke depressionLiver qi stagnation syndromeXingnao Kaiqiao acupunctureRepetitive transcranial magnetic stimulationDepression severitySleep qualityNeurotransmittersInflammatory factors
《新中医》 2026 (11)
47-55,9
金华市中医药科技计划项目(2025LC37)
评论